首页> 外文期刊>Gastrointestinal Endoscopy >Outcomes from a prospective trial of endoscopic radiofrequency ablation of early squamous cell neoplasia of the esophagus
【24h】

Outcomes from a prospective trial of endoscopic radiofrequency ablation of early squamous cell neoplasia of the esophagus

机译:食管早期鳞状细胞瘤内镜射频消融的前瞻性研究结果

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Radiofrequency ablation (RFA) is safe and effective for eradicating neoplasia in Barrett's esophagus. Objective: To evaluate RFA for eradicating early esophageal squamous cell neoplasia (ESCN) defined as moderate-grade squamous intraepithelial neoplasia (MGIN) and high-grade squamous intraepithelial neoplasia (HGIN) and early flat-type esophageal squamous cell carcinoma (ESCC). Design: Prospective cohort study. Setting: Tertiary referral center. Patients: Esophageal unstained lesions (USLs) were identified using Lugol's chromoendoscopy. Inclusion criteria were at least 1 flat (type 0-IIb) USL 3 cm or larger, USL-bearing esophagus 12 cm or less, and a consensus diagnosis of MGIN, HGIN, or ESCC by 2 expert GI pathologists. Exclusion criteria were previous endoscopic resection or ablation, stricture, or any nonflat mucosa. Interventions: Circumferential RFA creating a continuous treatment area (TA) including all USLs. At 3-month intervals thereafter, chromoendoscopy with biopsies followed by focal RFA of USLs, if present. Main Outcome Measurements: Complete response (CR) at 12 months defined as absence of MGIN, HGIN, or ESCC in the TA, CR after 1 RFA session, neoplastic progression from baseline, and adverse events. Results: Twenty-nine patients (14 male, mean age 60.3 years) with MGIN (n = 18), HGIN (n = 10), or ESCC (n = 1) participated. Mean USL length was 6.2 cm (TA 8.2 cm). At 3 months after 1 RFA session, 86% of patients (25/29) had a CR. At 12 months, 97% of patients (28/29) had a CR. There was no neoplastic progression. There were 4 strictures, all dilated to resolution. Limitations: Single-center study with limited number of patients. Conclusions: In patients with early ESCN (MGIN, HGIN, flat-type ESCC), RFA was associated with a high rate of histological complete response (97% of patients), no neoplastic progression, and an acceptable adverse event profile.
机译:背景:射频消融术(RFA)根除巴雷特食管肿瘤是安全有效的。目的:评价RFA根除早期食管鳞状细胞癌(ESCN),定义为中度鳞状上皮内瘤变(MGIN)和高度鳞状上皮内瘤变(HGIN)和早期扁平型食管鳞状细胞癌(ESCC)。设计:前瞻性队列研究。地点:第三级转诊中心。患者:使用Lugol色谱内窥镜检查鉴定食管未染色病变(USL)。纳入标准为至少1个扁平的(0-IIb型)USL 3 cm或更大,带有USL的食管12 cm或更小,并且由2位胃肠病学专家对MGIN,HGIN或ESCC进行共识性诊断。排除标准为先前的内镜切除或消融,狭窄或任何不平坦的粘膜。干预措施:周向RFA会创建包括所有USL的连续治疗区域(TA)。此后每3个月进行一次内窥镜检查,然后进行USL的局部RFA(如果存在)。主要结果测量:12个月时的完全缓解(CR)定义为TA中无MGIN,HGIN或ESCC,1次RFA疗程后CR,从基线开始的肿瘤进展以及不良事件。结果:29名MGIN(n = 18),HGIN(n = 10)或ESCC(n = 1)患者(14名男性,平均年龄60.3岁)参加了研究。 USL平均长度为6.2厘米(TA 8.2厘米)。 1次RFA疗程后3个月,有86%(25/29)的患者患有CR。在12个月时,有97%的患者(28/29)患有CR。没有肿瘤进展。有4条狭窄,所有狭窄都可以解决。局限性:单中心研究,患者数量有限。结论:在早期ESCN患者(MGIN,HGIN,扁平型ESCC)中,RFA与较高的组织学完全缓解率(97%的患者),无肿瘤进展和可接受的不良事件有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号